MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Cocrystal Pharma ROE Ratio 2011-2026 | COCP
Annual ROE Ratio Cocrystal Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -139.49 | -183.81 | -68.16 | -98.16 | -18.29 | -18.38 | -187.37 | -73.33 | -0.58 | -73.18 | -29.91 | -1.49 | 325.61 | 222.45 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 325.61 | -187.37 | -24.58 |
Quarterly ROE Ratio Cocrystal Pharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -135.64 | -147.8 | -139.99 | -87.12 | -100.69 | -75.38 | -56.67 | -40.55 | -51.97 | -49.82 | -87.27 | -66.6 | -71.46 | -64.9 | -19.96 | -14.63 | -19.72 | -19.94 | -22.09 | -15.53 | -22.46 | -24.29 | -23.53 | -1.26 | -4.05 | 0.08 | 3.96 | -7.12 | -2.47 | -1.54 | -1.68 | -1.78 | -70.68 | -70.66 | -71.67 | -73.18 | -27.08 | -25.55 | -23.96 | -29.91 | -50.06 | -88.09 | -15.4 | 27.2 | 38.58 | 88.28 | 28.82 | 35.02 | 37.77 | 29.15 | 37.45 | 124.55 | 214.82 | 302.33 | 302.9 | 111.28 | 90.27 | 20.53 | 0.48 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 302.9 | -147.8 | -7.3 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
63.85 | $ 0.77 | -4.12 % | $ 35.2 M |  Israel |
 |
Exelixis
EXEL
|
36.21 | $ 48.16 | 4.22 % | $ 13.1 B | USA |
 |
BioNTech SE
BNTX
|
-5.91 | $ 94.13 | 1.19 % | $ 22.8 B | Germany |
 |
Fortress Biotech
FBIO
|
13.66 | $ 2.39 | -0.42 % | $ 66.7 M | USA |
|
Forte Biosciences
FBRX
|
-113.75 | $ 24.02 | -8.22 % | $ 311 M | USA |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.9 | 1.4 % | $ 271 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.4 | -0.71 % | $ 3.71 B | USA |
 |
Genmab A/S
GMAB
|
21.38 | $ 26.43 | -2.33 % | $ 1.71 B |  Danmark |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
7.51 | $ 3.14 | - | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.51 | -0.85 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Gilead Sciences
GILD
|
37.48 | $ 131.33 | -2.04 % | $ 163 B | USA |
 |
Genprex
GNPX
|
-203.83 | $ 0.87 | 0.58 % | $ 811 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 21.17 | 2.47 % | $ 2.69 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Grifols, S.A.
GRFS
|
2.47 | $ 8.1 | 0.5 % | $ 5.51 B |  Spain |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 54.83 | 4.6 % | $ 4.93 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.57 | -2.48 % | $ 418 M | Britain |